<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345084</url>
  </required_header>
  <id_info>
    <org_study_id>EF 118</org_study_id>
    <nct_id>NCT01345084</nct_id>
  </id_info>
  <brief_title>Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab</brief_title>
  <acronym>NICAP</acronym>
  <official_title>A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary: to compare the overall survival defined as the time elapsed between the&#xD;
      randomization date and death due to any cause, in both treatment groups.&#xD;
&#xD;
      Secondary: to compare the progression-free survival, incidence of locoregional failure, site&#xD;
      of the first recurrence/progression, objective response rate assessment, quality of life&#xD;
      assessment and incidence of adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, superiority, national, open-label, randomized, and two-arm study.&#xD;
&#xD;
      Patients' enrollment will be performed only after approval by competent regulatory&#xD;
      authorities and it will last up to 12 months.&#xD;
&#xD;
      All patients taking part in the study must sign an informed consent. The patients will have&#xD;
      stage III or IV, unresectable head and neck SCC, performance status 0 or 1.&#xD;
&#xD;
      Randomization and treatment assignment will be performed by a company specifically contracted&#xD;
      for such purpose and will be per research site and disease stage, 1:1&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    change company strategy&#xD;
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months</time_frame>
    <description>Local control of disease will be measured by magnetic resonance imaging (MRI) and physical examination 6 weeks after treatment end.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clinical response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival; Incidence of locoregional failure; Site of the first recurrence or progression; Objective response rate assessment; EORTC quality of life questionnaires assessment; Incidence of several adverse events;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Carcinoma</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation therapy, cisplatin and nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months.&#xD;
Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week&#xD;
Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation therapy and cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week&#xD;
Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week</description>
    <arm_group_label>Radiation therapy and cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).</description>
    <arm_group_label>Radiation therapy, cisplatin and nimotuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m2, IV, doses every 3 weeks (a total of three doses)</description>
    <arm_group_label>Radiation therapy and cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Aged 18 to 75 years old;&#xD;
&#xD;
          -  Histological or cytological confirmation of SCC in oral cavity, oropharynx,&#xD;
             hypopharynx, or larynx;&#xD;
&#xD;
          -  Stages III or IV disease&#xD;
&#xD;
          -  Unresectability according to responsible surgeon or medical staff's opinion;&#xD;
&#xD;
          -  Performance status 0 or 1&#xD;
&#xD;
          -  Present indication for radiation therapy and chemotherapy treatment with cisplatin;&#xD;
&#xD;
          -  Adequate hepatic, renal and medullar functions, indicated by:&#xD;
&#xD;
          -  Life expectancy above 6 months.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Presence of nasopharyngeal, paranasal sinuses, or salivary glands carcinoma;&#xD;
&#xD;
          -  Presence of known distant metastasis;&#xD;
&#xD;
          -  Presence of any other active neoplasm or history of any tumor diagnosed in the last 5&#xD;
             years&#xD;
&#xD;
          -  Patients with inability to eat normally, in whom a gastric or enteral tubing was not&#xD;
             possible at least 2 weeks before their enrollment in the study;&#xD;
&#xD;
          -  Previous treatment with chemotherapy, radiation therapy, or EGFR inhibitors of any&#xD;
             pharmacological class;&#xD;
&#xD;
          -  Presence of serious comorbidity that, in the investigator's opinion, will put the&#xD;
             patient at risk or will jeopardize protocol compliance;&#xD;
&#xD;
          -  Active known seropositivity for HIV, hepatitis B or C&#xD;
&#xD;
          -  Presence of a significant neurological or psychiatric disease, as per the&#xD;
             investigator's judgment;&#xD;
&#xD;
          -  Hypersensitivity or allergy to any of the study treatments;&#xD;
&#xD;
          -  Presence of uncontrolled hypercalcemia;&#xD;
&#xD;
          -  Pregnancy or breastfeeding;&#xD;
&#xD;
          -  Female patients of childbearing potential who wish to become pregnant or are&#xD;
             unwilling, as well as their partners, to use an appropriate contraceptive method&#xD;
             throughout the study period;&#xD;
&#xD;
          -  Participation in any clinical trial in the last 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Girotto</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Base São José do Rio Preto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Erasto Gaetner</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Pio XII - Hospital de Câncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Amaral Carvalho</name>
      <address>
        <city>Jau</city>
        <state>São Paulo</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Mogi das Cruzes</name>
      <address>
        <city>Mogi das Cruzes</city>
        <state>São Paulo</state>
        <zip>08730-500</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base São José do Rio Preto</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Federal de Bonsucesso</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>210041-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Câncer de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2011</study_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <name_title>Fernanda Martinez</name_title>
    <organization>Eurofarma Laboratórios</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

